Thomas Boerner1, Constantinos Zambirinis1, Johan Gagnière2, Joanne F Chou3, Mithat Gonen3, Nancy E Kemeny4, Andrea Cercek4, Louise C Connell4, Thomas P Kingham1, Peter J Allen5, Vinod P Balachandran1, Jeffrey Drebin1, William R Jarnagin1, Michael I D'Angelica6. 1. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Digestive and Hepatobiliary Surgery, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France; U1071 Inserm/Clermont-Auvergne University, Clermont-Ferrand, France. 3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Surgery, Duke University, Durham, NC, USA. 6. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: dangelim@mskcc.org.
Abstract
BACKGROUND: The utility of adjuvant chemotherapy after resection of colorectal liver metastasis (CLM) in patients with rapid recurrence after adjuvant chemotherapy for their primary tumor is unclear. The aim of this study was to evaluate the oncologic benefit of adjuvant hepatic arterial plus systemic chemotherapy (HAIC + Sys) in patients with early CLM. METHODS: A retrospective analysis of patients with early CLM (≤12 months of adjuvant chemotherapy for primary tumor) who received either HAIC + Sys, adjuvant systemic chemotherapy alone (Sys), or active surveillance (Surgery alone) following resection of CLM was performed. Recurrence and survival were compared between treatment groups using Kaplan-Meier methods and Cox proportional hazards models. RESULTS: Of 239 patients undergoing resection of early CLM, 79 (33.1%) received HAIC + Sys, 77 (32.2%) received Sys, and 83 (34.7%) had Surgery alone. HAIC + Sys was independently associated with reduced risk of RFS events (adjusted hazard ratio [HRadj]: 0.64, 95%CI:0.44-0.94, p = 0.022) and all-cause mortality (HRadj: 0.54, 95%CI:0.36-0.81, p = 0.003) compared to Surgery alone patients. Largest tumor >5 cm (HRadj: 2.03, 95%CI: 1.41-2.93, p < 0.001) and right-sided colon tumors (HRadj: 1.93, 95%CI: 1.29-2.89, p = 0.002) were independently associated with worse OS. CONCLUSION: Adjuvant HAIC + Sys after resection of early CLM that occur after chemotherapy for node-positive primary is associated with improved outcomes.
BACKGROUND: The utility of adjuvant chemotherapy after resection of colorectal liver metastasis (CLM) in patients with rapid recurrence after adjuvant chemotherapy for their primary tumor is unclear. The aim of this study was to evaluate the oncologic benefit of adjuvant hepatic arterial plus systemic chemotherapy (HAIC + Sys) in patients with early CLM. METHODS: A retrospective analysis of patients with early CLM (≤12 months of adjuvant chemotherapy for primary tumor) who received either HAIC + Sys, adjuvant systemic chemotherapy alone (Sys), or active surveillance (Surgery alone) following resection of CLM was performed. Recurrence and survival were compared between treatment groups using Kaplan-Meier methods and Cox proportional hazards models. RESULTS: Of 239 patients undergoing resection of early CLM, 79 (33.1%) received HAIC + Sys, 77 (32.2%) received Sys, and 83 (34.7%) had Surgery alone. HAIC + Sys was independently associated with reduced risk of RFS events (adjusted hazard ratio [HRadj]: 0.64, 95%CI:0.44-0.94, p = 0.022) and all-cause mortality (HRadj: 0.54, 95%CI:0.36-0.81, p = 0.003) compared to Surgery alone patients. Largest tumor >5 cm (HRadj: 2.03, 95%CI: 1.41-2.93, p < 0.001) and right-sided colon tumors (HRadj: 1.93, 95%CI: 1.29-2.89, p = 0.002) were independently associated with worse OS. CONCLUSION: Adjuvant HAIC + Sys after resection of early CLM that occur after chemotherapy for node-positive primary is associated with improved outcomes.
Authors: Marc Peeters; Timothy Jay Price; Andrés Cervantes; Alberto F Sobrero; Michel Ducreux; Yevhen Hotko; Thierry André; Emily Chan; Florian Lordick; Cornelis J A Punt; Andrew H Strickland; Gregory Wilson; Tudor-Eliade Ciuleanu; Laslo Roman; Eric Van Cutsem; Valentina Tzekova; Simon Collins; Kelly S Oliner; Alan Rong; Jennifer Gansert Journal: J Clin Oncol Date: 2010-10-04 Impact factor: 44.544
Authors: Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Murielle Mauer; Erik Tanis; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger Journal: Lancet Oncol Date: 2013-10-11 Impact factor: 41.316
Authors: M Ychou; W Hohenberger; S Thezenas; M Navarro; J Maurel; C Bokemeyer; E Shacham-Shmueli; F Rivera; C Kwok-Keung Choi; A Santoro Journal: Ann Oncol Date: 2009-06-30 Impact factor: 32.976
Authors: Andreas Andreou; Scott Kopetz; Dipen M Maru; Su S Chen; Giuseppe Zimmitti; Antoine Brouquet; Junichi Shindoh; Steven A Curley; Christopher Garrett; Michael J Overman; Thomas A Aloia; Jean-Nicolas Vauthey Journal: Ann Surg Date: 2012-10 Impact factor: 12.969
Authors: Sharlene Gill; Charles L Loprinzi; Daniel J Sargent; Stephan D Thomé; Steven R Alberts; Daniel G Haller; Jacqueline Benedetti; Guido Francini; Lois E Shepherd; Jean Francois Seitz; Roberto Labianca; Wei Chen; Stephen S Cha; Michael P Heldebrant; Richard M Goldberg Journal: J Clin Oncol Date: 2004-04-05 Impact factor: 44.544
Authors: Alberto F Sobrero; Joan Maurel; Louis Fehrenbacher; Werner Scheithauer; Yousif A Abubakr; Manfred P Lutz; M Eugenia Vega-Villegas; Cathy Eng; Ernst U Steinhauer; Jana Prausova; Heinz-Josef Lenz; Christophe Borg; Gary Middleton; Hendrik Kröning; Gabriele Luppi; Oliver Kisker; Angela Zubel; Christiane Langer; Justin Kopit; Howard A Burris Journal: J Clin Oncol Date: 2008-04-07 Impact factor: 44.544
Authors: Eric Van Cutsem; Josep Tabernero; Radek Lakomy; Hans Prenen; Jana Prausová; Teresa Macarulla; Paul Ruff; Guy A van Hazel; Vladimir Moiseyenko; David Ferry; Joe McKendrick; Jonathan Polikoff; Alexia Tellier; Rémi Castan; Carmen Allegra Journal: J Clin Oncol Date: 2012-09-04 Impact factor: 44.544